



Complement Therapeutics Ltd announces appointment of Steve Axon to its Board of Directors

London, England – 18th July 2022 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company, announced today the appointment of Steve Axon to its Board of Directors. Steve joined the Board on June 1st 2022 as an independent director and will support CTx in addressing unmet needs in complement mediated diseases such as geographic atrophy due to dry age-related macular degeneration, a major cause of vision loss and blindness globally.

Steve is a seasoned biopharmaceutical executive with over 20 years experience in the sector with particular expertise and experience in complement driven diseases, consequent to his previous role as Chief Business Officer at Apellis Pharmaceuticals and has recently been appointed as CEO of Glycomine.

Dr Rafiq Hasan, CEO, Complement Therapeutics Ltd commented, 'It is a real pleasure and privilege to welcome Steve to our Board. His expertise and experience in both complement mediated conditions and the sector more broadly will be invaluable to the company as we drive forward our novel pipeline and analytics platform'.

Steve Axon, independent director, commented 'I am excited to be joining the Board of CTx at such an exciting time and look forward to working with the growing team to develop innovative medicines addressing significant unmet need in both ophthalmology and broader complement driven diseases'.

-Ends-

For more information please contact:

Complement Therapeutics Ltd

Dr Rafiq Hasan, CEO

Email: rafiq@complementtx.com

Notes to Editor

About Complement Therapeutics Ltd

Complement Therapeutics (CTx) is an early stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases as well as developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform.

The Company is backed by Forbion and Biogeneration Ventures, two of Europe's leading investors and is based on the pioneering research of its founders into novel targets within the complement cascade and its quantification. The CPM platform employs a unique methodology to quantify over 30 complement cascade proteins.

Our lead investigational product (CTx001) is a gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.